Zydus Cadila gets USFDA nod for multiple sclerosis drug
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the U.S. Food and Drug Administration (USFDA) to market Dimethyl Fumarate DelayedRelease Capsules, (US RLD: Tecfidera®) in the strengths of 120 mg and 240 mg.Dimethyl Fumarate Delayed-Release Capsules are indicated for the treatment of patients with relapsing forms of multiple...
Ahmedabad: Drugmaker, Zydus Cadila, has recently announced that the company has received final approval from the U.S. Food and Drug Administration (USFDA) to market Dimethyl Fumarate DelayedRelease Capsules, (US RLD: Tecfidera®) in the strengths of 120 mg and 240 mg.
Dimethyl Fumarate Delayed-Release Capsules are indicated for the treatment of patients with relapsing forms of multiple sclerosis and will be manufactured at the group's manufacturing facility at the SEZ, Matoda.
Read also: Zydus Cadila anti-cancer drug Palbociclib gets tentative USFDA nod
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd